Safety and Outcomes With Combination Therapy With Sarilumab and Baricitinib for Severe COVID-19 Respiratory Infection in Cancer Patients
CONCLUSION: Our study explores the potential safe combination use of different immune modulators targeting multiple pathways of the inflammatory cascade for severe and refractory COVID-19 respiratory infections in high-risk oncology patients. The small number of patients in our observational study was a limitation. A larger sample of patients will be needed to conclude more precisely the efficacy of the combination therapy of sarilumab and baricitinib for refractory cases of severe COVID-19 respiratory infection. Moreover, exploring other cytokine release signaling pathway targets may be the key to significantly reducing inflammation and further pulmonary fibrosis with chronic unbearable respiratory sequela.PMID:37817417 | DOI:10.1177/10732748231205864
Source: Cancer Control - Category: Cancer & Oncology Authors: Ana Paula Velez Guy Handley Austin Morison Ju Hee Katzman Olga Kinkhova Rod Quiltz John Greene Yanina Pasikhova Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Coronavirus | Covid Vaccine | COVID-19 | Health Insurance | HIPAA | Immunotherapy | Insurance | Respiratory Medicine | Study | Vaccines